-
Bio-Thera Solutions’ BAT8006 Shows Positive Phase I Results in Solid Tumor Treatment
•
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced positive Phase I clinical data for BAT8006 (Folate-Receptor-α-ADC) at the Bethune Obstetrics and Gynecology Forum in China. The study evaluated the safety and efficacy of the antibody-drug conjugate (ADC) in a dose escalation trial. BAT8006: A Promising ADC for Solid TumorsBAT8006 is…
-
Vcanbio Receives Orphan Drug Designation for VUM02 in Idiopathic Pulmonary Fibrosis Treatment
•
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has received orphan drug designation (ODD) from the US FDA for its VUM02 (human umbilical cord-derived mesenchymal stem cells), a Category 1 therapeutic biologic product for the treatment of idiopathic pulmonary fibrosis (IPF). VUM02: An Innovative…
-
Asieris Pharmaceuticals’ Hexvix Meets Primary Endpoint in Phase III Bladder Cancer Study
•
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed that a Phase III study for Hexvix (APL-1706) in bladder cancer diagnosis has successfully reached its primary endpoint. Study Design and OutcomesThe prospective, subject-controlled, multi-center Phase III study compared the detection rates of APL-1706 combined with blue light cystoscopy and…
-
Eli Lilly Completes Acquisition of Dice Therapeutics for $2.0 Billion
•
Pharmaceutical giant Eli Lilly (NYSE: LLY) has successfully concluded the purchase of US-based Dice Therapeutics (NASDAQ: DICE) by acquiring 88.4% of the company’s issued and outstanding shares in a transaction valued at $2.0 billion. This strategic acquisition allows Lilly to incorporate Dice’s Delscape platform, which is focused on the development…
-
Sichuan Kelun-Biotech’s SKB264 Achieves Primary Endpoint in Phase III TNBC Study
•
Sichuan Kelun Pharmaceutical Co., Ltd’s innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), has announced that its Phase III clinical study for SKB264 (MK-2870) has reached its primary endpoint. The study, which is a randomized, controlled, open, multi-center trial, evaluated SKB264 in patients with irresectable local advanced,…
-
Huadong Medicine’s HDM3001, a Biosimilar to Stelara, Accepted for Review by NMPA
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA) has accepted a market filing for HDM3001 (QX001S), a biosimilar version of Johnson & Johnson’s Stelara (ustekinumab), for the treatment of moderate to severe plaque psoriasis. Market Potential and Clinical ProgressThe originator drug, Stelara,…
-
Cascade Pharmaceuticals Secures RMB140 Million in Financing to Advance FXR Agonist Clinical Trials
•
Shanghai-based sino-foreign joint venture, Cascade Pharmaceuticals, Inc., has reportedly raised RMB140 million in a recent financing round. The investors included a prestigious group of Puhua Capital, CAS Investment, HD Capital, Lapam Capital, and New Act Investment. The funds raised will be directed towards intensifying Phase II clinical studies for their…
-
Migrasome Therapeutics Secures Over RMB100 Million in Angel+ Funding Round
•
Beijing-based biotech startup Migrasome Therapeutics has reported raising upwards of RMB100 million in its angel + funding round. The round was led by ZGC Co-Innovation Fund and included contributions from notable investors such as Tsinghua Capital, Qiangkong Tiancheng Asset Management, BSTIG, and Qihang Investment. Investor Confidence in Migrasome TherapeuticsThe significant…
